In the News

Childhood leukemia expert Melvyn Greaves received The Society of Memorial Sloan Kettering Prize at the 2018 Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK) commencement.

Multiple copies of a gene called <em>YES1</em> appear to be responsible for certain precision drugs losing their effectiveness.

This study demonstrates how clonal hematopoiesis (CH)–derived mutations could lead to erroneous reporting and treatment recommendations when tumor-only sequencing is employed. If data about the blood are not part of test results, mutations present in the blood may be misread as mutations in the tumor, which can potentially affect the therapies patients receive. Data presented at the annual meeting of the American Society of Clinical Oncology by Ahmet Zehir, PhD, Director of Clinical Bioinformatics at Memorial Sloan Kettering Cancer Center (MSK) was simultaneously published in <i>JAMA Oncology</i> on June 5.

A blood condition related to aging can lead to misinterpreting tumor data.

Couldn't make it to the American Society of Clinical Oncology's annual meeting this year? Read this summary of some main takeaways.

The findings will change how women with intermediate-risk breast cancer are treated.

Tumors with a biomarker called high microsatellite instability have been linked to inherited cancer mutations.

A clinical trial provides evidence that blocking a protein called PI3K can be an effective treatment strategy for breast cancer.

Degrees were presented and awards were given at the 39th annual ceremony, held on May 30.

By uncovering the root cause of cytokine release syndrome, MSK researchers have found a way to stop it.